Along those lines suggested by David I would say these crystals are way too big. Try freezing some when they are smaller. It would also be worth trying to freeze in meshes to support the fragile plate instead of conventional loops. J?rgen
...................... J?rgen Bosch Johns Hopkins University Bloomberg School of Public Health Department of Biochemistry & Molecular Biology Johns Hopkins Malaria Research Institute 615 North Wolfe Street<x-apple-data-detectors://4>, W8708 Baltimore, MD 21205<x-apple-data-detectors://5/0> Office: +1-410-614-4742<tel:%2B1-410-614-4742> Lab: +1-410-614-4894<tel:%2B1-410-614-4894> Fax: +1-410-955-2926<tel:%2B1-410-955-2926> http://lupo.jhsph.edu<http://lupo.jhsph.edu/> On Apr 24, 2015, at 03:52, Hargreaves, David <[email protected]<mailto:[email protected]>> wrote: The crystals don't look that bad in my opinion. Maybe the cryo step is sub optimal? Try using large loops (reduces surface tension forces during transfer). Butane 2,3 diol is a good cryo to try. Maybe shoot them at room temp (in situ) to get an idea of how they diffract before you manipulate them. Good luck! From: CCP4 bulletin board [mailto:[email protected]] On Behalf Of Prerana G. Sent: 24 April 2015 04:01 To: [email protected]<mailto:[email protected]> Subject: [ccp4bb] Thin plate crystals Dear all, I am working on a protein (40kDa) which forms very thin plate shaped crystals which diffracts at very low resolution. Protein concentration that i have used for crystallisation is approx. 8mg/ml. I have attached the picture of the protein crystal. How can I improve upon the shape of the crystal? ________________________________ AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 2 Kingdom Street, London, W2 6BD. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking compliance with our Code of Conduct and policies.
